Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide.

ABSTRACT:

Background

Growing evidence indicates a causal relationship between SARS-CoV-2 infection and myocarditis. Post-authorization safety data have also identified myocarditis as a rare safety event following mRNA COVID-19 vaccination, particularly among adolescent and young adult males after dose 2. We further evaluated the potential risk by querying the Moderna global safety database for myocarditis/myopericarditis reports among mRNA-1273 recipients worldwide.

Methods

Myocarditis/myopericarditis reports from December 18, 2020, to February 15, 2022, were reviewed and classified. The reported rate after any known mRNA-1273 dose was calculated according to age and sex, then compared to a population-based incidence rate to calculate observed-to-expected rate ratios (RR).

Results<

SUBMITTER: Straus W 

PROVIDER: S-EPMC9384217 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature